Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.58 |
| ▸ | CHEK1 | O14757 | 10/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.51 |
| ▸ | MELK | Q14680 | 1/20 | 0.51 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.51 |
| ▸ | TYMS | P04818 | 2/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL669508 | 0.90 | PARP1 (0.70) | PARP1CHEK1JAK2RPS6KA3MELK | |
| SCHEMBL57212 | 0.74 | PARP1 (1.00) | PARP1CHEK1JAK2RPS6KA3MELK | |
| SCHEMBL29365341 | 0.74 | PARP1 (1.00) | PARP1CHEK1JAK2RPS6KA3MELK | |
| Hydrochloric Acid SCHEMBL30294983 | 0.73 | PARP1 (0.95) | PARP1CHEK1JAK2RPS6KA3MELK | |
| Benzene SCHEMBL670928 | 0.73 | PARP1 (0.95) | PARP1CHEK1JAK2RPS6KA3MELK | |
| Hydrochloric Acid SCHEMBL2455495 | 0.73 | PARP1 (0.95) | PARP1CHEK1JAK2RPS6KA3MELK | |
| Potassium SCHEMBL3099047 | 0.73 | PARP1 (0.95) | PARP1CHEK1JAK2RPS6KA3MELK | |
| SCHEMBL670718 | 0.73 | PARP1 (0.95) | PARP1CHEK1JAK2RPS6KA3MELK | |
| Hydrochloric Acid SCHEMBL7380702 | 0.73 | PARP1 (0.95) | PARP1CHEK1JAK2RPS6KA3MELK | |
| SCHEMBL27946369 | 0.73 | PARP1 (0.95) | PARP1CHEK1JAK2RPS6KA3MELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| EP-1904449-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007008502-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | CHEK1, CHEK2, CDKN1A | PARP1 193/4885CHEK1 1/4885JAK2 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.